Section - CAP Smart Takes

01. Safety and Efficacy of Agomelatine in Children and Adolescents With Major Depressive Disorder

Published on September 28, 2022 Certification expiration date: September 28, 2028

David R. Rosenberg, M.D.

Chair of the Department of Psychiatry & Behavioral Neuroscience - Wayne State University School of Medicine

Key Points

Efficacy of agomelatine in adolescents 12–17 years of age:
◦ Agomelatine 25 mg/day was comparably effective to fluoxetine.
Efficacy in children 7–11:
◦ No efficacy
Side effects:
◦ In contrast with adults, there was no change in liver enzymes in children and adolescents.

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Text version

Hi! David Rosenberg here for the Psychopharmacology Institute; we are excited to introduce something new called CAP Smart Takes or Child and Adolescent Psychiatry Smart Takes.

So, what exactly is a CAP Smart Take? First and foremost, they are short, quick, and clinically relevant to all of you who treat various childhood-onset psychiatric disorders, from childhood and adolescent psychosis to OCD, eating disorders, bipolar disorder, depression, anxiety, autism spectrum disorder, and many more. I hope I am not leaving any of your favorites out. The goal is not to be encyclopedic but short and to the point. CAP Smart Takes will give you the big picture and key points that are most clinically relevant, including newer alternative approaches for a particular childhood disorder. We will not go into a detailed methodology; this is not an ivory tower with armchair theories. We will drill down on what can immediately inform your

Unlock this CAP Smart Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Next Section

02. The Knowns and Unknowns of SSRI Treatment in Young People With Depression and Anxiety

Learning Objectives:

After completing this activity, the learner will be able to:

Assess the safety and effectiveness of agomelatine in youth with major depressive disorder.
Discuss particular considerations when prescribing SSRIs in children.
Recognize the long-term symptom control and safety of MPH-MLR in preschool children 4 to <6 years with ADHD.
Compare response rates of major depressive episodes in youth with bipolar disorder treated with second-generation antipsychotics.
Identify genetic, clinical, and sociodemographic factors associated with stimulant initiation, discontinuation, and switch to nonstimulants in children, adolescents, and adults with ADHD.

Original Release Date: September 28, 2022

Review and Re-release Date: September 28, 2025

Expiration Date: September 28, 2028

Expert: David Rosenberg, M.D.

Medical Editor: Lorena Rodriguez, M.D.

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.